AMENDED CLAIMS

[received by the International Bureau on 18 December 2000 (18.12.00); original claim 1 amended; remaining claims unchanged (4 pages)]

1. A compound of formula I,

ompound of formula I,

R5c R5a R5e

R5c R5a R5e

R5c R5a R5e

R6

wherein

5

10

15

 R^1 represents $C_{1\cdot 12}$ alkyl, $-(CH_2)_a$ -aryl, or $-(CH_2)_a$ -Het¹ (all of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, halo, cyano, nitro, $C_{1\cdot 4}$ alkyl and/or $C_{1\cdot 4}$ alkoxy);

a represents 0, 1, 2, 3, or 4;

Het¹ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

 R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} and R^{5f} independently represent H or C_{1-3} alkyl;

 R^2 and R^3 independently represent H, C_{1-4} alkyl (optionally substituted and/or terminated with one or more nitro or cyano groups), OR^7 , $N(R^{7a})R^{7b}$, $OC(O)R^8$ or together form $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$;

73

 R^7 and R^8 independently represent H, C_{1-6} alkyl or $-(CH_2)_b$ -aryl (which latter two groups are optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

10 R^{7a} and R^{7b} independently represent H or C₁₋₆ alkyl; b represents 0, 1, 2, 3 or 4;

 R^4 represents H of C_{1-6} alkyl;

- D represents H, C_{1-4} alkyl, $-OR^9$, or $-(CH_2)_cN(R^{10})(R^{11})$; R^9 represents H, C_{1-6} alkyl, $-C(O)R^{12}$, $-(CH_2)_d$ -aryl or $-(CH_2)_d$ -Het² (which latter three groups are optionally substituted by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)R^{13}$, $C(O)OR^{14}$ and/or $-N(H)S(O)_cR^{15}$);
- 20 R^{10} represents H, C_{1-6} alkyl, $-(CH_2)_f$ aryl, $-C(NH)NH_2$, $-S(O)_2R^{15a}$, $-[C(O)]_gN(R^{16})(R^{17})$, $-C(O)R^{18}$ or $-C(O)OR^{19}$; e represents 0, 1 or 2; g represent 1 or 2;
- R¹¹ represents H, C₁₋₆ alkyl, -C(O)R²⁰ or -(CH₂)_h-aryl (which latter group is optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C₁₋₆ alkyl and/or C₁₋₆ alkoxy);
 - R^{12} , R^{13} , R^{14} , R^{16} , R^{17} , R^{18} , R^{19} and R^{20} independently represent H, C_{1-6} alkyl, Het³ or $-(CH_2)_j$ -aryl (which latter three groups are optionally

substituted and/or terminated (as appropriate) by one or more substituents selected from -OH cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

 R^{15} and R^{15a} independently represent C_{1-6} alkyl, aryl or $-(CH_2)_k$ -aryl (all of which are all optionally substituted and/or terminated (as appropriate) by one or more substituents chosen from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

c, d, f, h, j and k independently represent 0, 1, 2, 3 or 4;

Het² and Het³ independently represent five to ten-membered heterocyclic rings containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

R⁶ represents one or more optional substituents selected from -OH, cyano, halo, amino, nitro, C₁₋₆ alkyl (optionally terminated by N(H)C(O)OR^{20a}), C₁₋₆ alkoxy, -C(O)N(H)R²¹, -NHC(O)N(H)R²², -N(H)S(O)₂R²³ and/or -OS(O)₂R²⁴;

 R^{21} and R^{22} independently represent H or C_{1-6} alkyl; R^{20a} , R^{23} and R^{24} independently represent C_{1-6} alkyl;

20

A represents a single bond, C_{1-6} alkylene, $-N(R^{25})(CH_2)_m$, $-O(CH_2)_m$ or $-(CH_2)_mC(H)(OR^{25})(CH_2)_n$ (in which latter three groups, the $-(CH_2)_m$ group is attached to the bispidine nitrogen atom and which latter four groups are optionally substituted by one or more -OH groups);

B represents a single bond, C_{1-4} alkylene, $-(CH_2)_pN(R^{26})$ -, $-(CH_2)_pS(O)_q$ -, $-(CH_2)_pO$ - (in which three latter groups, the $-(CH_2)_p$ - group is attached to the carbon atom bearing D and R⁴), $-C(O)N(R^{26})$ - (in which latter group, the -C(O)- group is attached to the carbon atom bearing D and R⁴),

15

 $-N(R^{26})C(O)O(CH_2)_p$ - or $-N(R^{26})(CH_2)_p$ - (in which latter two groups, the $N(R^{26})$ group is attached to the carbon atom bearing D and R^4); m, n and p independently represent 0, 1, 2, 3 or 4;

q represents 0, 1 or $\frac{1}{2}$;

 R^{25} represents H, C₆ alkyl or C(O)R²⁷;

 R^{26} represents H or C_{1-6} alkyl;

 R^{27} represents H, C_{1-6} alkyl, Het⁴ or $-(CH_2)_r$ -aryl (which latter two groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

Het⁴ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

r represents 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable derivative thereof;

provided that:

- (a) R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e} and R^{5f} do not all simultaneously represent H;
- 20 (b) R^{5a} and R^{5b} do not represent C₁₋₃ alkyl when R^{5c}, R^{5d}, R^{5e} and R^{5f} all represent H; and
 - (c) when D represents -OH or $-(CH_2)_cN(R^{10})R^{11}$ in which c represents 0, then:-
 - (i) A does not represent $-N(R^{25})(CH_2)_{m}$, $-O(CH_2)_{m}$ or
- $-(CH_2)_mC(H)(OR^{25})(CH_2)_n$ (in which n is 0); and/or
 - (ii) p does not represent 0 when B represents $-(CH_2)_pN(R^{26})_{-}$,

 $-(CH_2)_pS(O)_q-$ or $-(CH_2)_pO-$.

2. A compound as claimed in Claim 1, wherein R^1 represents optionally substituted - $(CH_2)_a$ -phenyl, in which a is 0, 1, 2 or 3, or optionally substituted, optionally unsaturated, linear, branched or cyclic, C_{1-8} alkyl (which latter group may also be interrupted by an oxygen atom).

3. A compound as claimed in Claim 1 or Claim 2, wherein R² represents

4. A compound as claimed in any one of the preceding claims, wherein R³ represents H.

5. A compound as claimed in any one of the preceding elaims, wherein R^4 represents H or C_{1-3} alkyl.

6. A compound as claimed in any one of the preceding claims, wherein R^{5a} and R^{5b} either both represent H or both represent methyl.

7. A compound as claimed in any one of the preceding claims, wherein R^{5c} , R^{5d} , R^{5e} and R^{5f} independently represent H or C_{1-2} alkyl.

8. A compound as claimed in any one of the preceding claims, wherein R^6 represents—one or more substituents selected from C_{1-6} alkyl (which alkyl group is optionally terminated by a $N(H)C(O)OR^{20a}$ group (in which R^{20a} represents C_{1-5} alkyl)), cyano, nitro, amino, $C(O)N(H)R^{21}$ and/or

 $-N(H)S(O)_2R^{23}$; wherein s is 1, 2, 3, 4, 5.

9. A compound as claimed in any one of the preceding elaims, wherein X represents O.

20

٤

10. A compound as claimed in any one of the preceding claims, wherein A represents a single bond or linear, or branched, C14 alkylene (which group is also optionally interrupted by O).

11. A compound as claimed in any one of the preceding claims, wherein B represents a single bond, C_{1-4} alkylene, $-(CH_2)_pO$ - or $-(CH_2)_pN(R^{26})$ - (in which latter two cases p is 1, 2 or 3).

12. A compound as claimed in any one of the preceding claims, wherein D represents H, OR9 (in which R9 represents H, C1-3 alkyl or optionally substituted phenyl) or $N(H)R^{10}$ (in which R^{10} represents H or C_{1-4} alkyl).

pharmaceutical formulation including a compound as defined in any of Claims 1 to 12 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

14. A pharmaceutical formulation for use in the prophylaxis or the treatment of an arrhythmia, comprising a compound as defined in any one-

15. A compound as defined in any one pharmaceutical

16. A compound as defined in any one of Claims 1 to 12 for use in the prophylaxis or the theatment of an arrhythmia.

17. The use of a compound as defined in any of one Claims 1 to 12 as active ingredient in the manufacture of a medicament for use in the prophylaxis or the treatment of an arrhythmia.


10

5

18. The use as claimed in Claim 17, wherein the arrhythmia is an atrial or a ventricular arrhythmia.

19. A method of prophylaxis or treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound as defined in any one of Claims 1 to 12 to a person suffering from, or susceptible to, such a condition.

- 20. A process for the preparation of a compound of formula I as defined in Claim 1 which comprises:
 - (a) reaction of a compound of formula II,




wherein R², R³, R⁴, R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R⁶, A, B and D are as defined in Claim 1 with a compound of formula III,


$$R^1XC(O)L^1$$
 III

wherein L^1 represents a leaving group and R^1 and X are as defined in Claim 1;

(b) for compounds of formula I in which A represents CH_2 and D represents -OH or $-N(H)R^{10}$, wherein R^{10} is as defined in Claim 1, reaction of a compound of formula IV,



wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} and X are as defined in Claim 1, with a compound of formula V,




10

5


wherein Y represents O or $N(R^{10})$ and R^4 , R^6 , R^{10} and B are as defined in Claim 1;

(c) reaction of a compound of formula IV, as defined above, with a compound of formula VI,




wherein L^2 represents a leaving group and R^4 , R^6 , A, B and D are as defined in Claim 1;

5 (d) for compounds of formula I in which D represents H or OH and R⁴ represents H, reduction of a compound of formula VII,



- wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} , R^6 , A, B and X are as defined in Claim 1;
 - (e) for compounds of formula I in which one of R² and R³ represents H or OH and the other represents H, reduction of a corresponding compound of formula VIII,

10



wherein R^1 , R^4 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} , R^6 , A, B, D and X are as defined in Claim 1;


(f) for compounds of formula I in which R^2 and/or R^3 represent $OC(O)R^8$ and R^8 is as defined in Claim 1, coupling of a corresponding compound of formula I in which R^2 and/or R^3 (as appropriate) represent OH and a compound of formula VIIIA,

 R^8CO_2H VIIIA

wherein R⁸ is as defined in Claim 1;

(g) for compounds of formula I in which D represents -(CH₂)_cNH₂, reduction of a corresponding compound of formula IX,

10



wherein c, R^1 , R^2 , R^3 , R^4 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} , R^6 , A, B and X are as defined in Claim 1;

(h) for compounds of formula I in which D represents $-N(R^{11})C(O)NH(R^{17})$, in which R^{11} and R^{17} are as defined in Claim 1, except that R^{11} does not represent $C(O)R^{20}$, reaction of a corresponding compound of formula I in which D represents $-N(R^{11})H$, in which R^{11} is as defined in Claim 1 except that is does not represent $C(O)R^{20}$ in which R^{20} is as defined in Claim 1, with a compound of formula X,

$$R^{17}N = C = O X$$

wherein R^{17} is as defined in Claim 1;

- (i) for compounds of formula I in which D represents -N(H)[C(O)]₂NH₂, reaction of a corresponding compound of formula I in which D represents -NH₂ with oxalic acid diamide;
- (j) for compounds of formula I in which D represents -N(R¹¹)C(O)R¹⁸, in which R¹¹ and R¹⁸ are as defined in Claim 1, except that R¹¹ does not represent C(O)R²⁰, reaction of a corresponding compound of formula I in which D represents -N(R¹¹)H, in which R¹¹ is as defined in Claim 1 except that it does not represent C(O)R²⁰, with a compound of formula XI,

15

20

wherein R^x represents a suitable leaving group and R^{18} is as defined in Claim 1;

(k) for compounds of formula I in which D represents $-N(H)R^{10}$ and R^{10} is as defined in Claim 1 except that it does not represent H or $-C(NH)NH_2$, reaction of a corresponding compound of formula I wherein D represents $-NH_2$ with a compound of formula XIA,

 $R^{10a}L^1$ XIA

wherein R^{10a} represents R^{10} as defined in Claim 1, except that it does not represent H or $-C(NH)NH_2$ and L^1 is as defined above;


- (1) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a corresponding compound of formula I;
- (m) for compounds of formula I which are C_{1-4} alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XII,

R^aHal XII


wherein R^a represents C₁₋₄ alkyl and Hal represents Cl, Br or I;

(n) for compounds of formula I in which D and R⁴ both represent H, A represents C_{1-6} alkylene, B represents $-N(R^{26})(CH_2)_p$ - and R^{26} and p are as defined in Claim 1, reaction of a compound of formula XIII,

15



wherein A^a represents C_{1-6} alkylene and R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} , R^{26} and X are as defined in Claim 1 with a compound of formula XIV,



wherein R⁶ and p are as defined in Claim 1 and Hal is defined above;

(o) reaction of a compound of formula II, as defined above, with a compound of formula XV,

$$R^{1}XH$$
 XV

wherein R^1 and X are as defined in Claim 1, in the presence of 1,1'-carbonyldiimidazole;


(p) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted - $(CH_2)_d$ -aryl or optionally substituted - $(CH_2)_d$ -Het², reaction of a corresponding compound of formula I, in which D represents OH with a compound of formula XVI,

15

•

wherein R^{9a} represents optionally substituted C_{1-6} alkyl, optionally substituted - $(CH_2)_d$ -aryl or optionally substituted - $(CH_2)_d$ -Het², and d and Het² are as defined in Claim 1;

(q) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted - $(CH_2)_d$ -aryl or optionally substituted - $(CH_2)_d$ -Het², reaction of a compound of formula XVII,



wherein L^2 is as defined above and R^1 , R^2 , R^3 , R^4 , R^{5a} , R^{5b} , R^{5c} , R^{5d} , R^{5e} , R^{5f} , R^6 , X, A and B are as defined in Claim 1 with a compound of formula XVI as defined above;

(r) for compounds of formula I in which R^9 represents $C(O)R^{12}$ and R^{12} is as defined in Claim 1, reaction of a corresponding compound of formula I in which D represents OH with a compound of formula XVIII,

 $R^{12}CO_2H$ XVIII

wherein R¹² is as defined in Claim 1;

(s) for compounds of formula I in which one or both of R^2 and R^3 represent $-N(R^{7a})R^{7b}$ in which one or both of R^{7a} and R^{7b} represents C_{1-6} alkyl, alkylation of a corresponding compound of formula I in which R^2




and/or R^3 represent $-N(R^{7a})R^{7b}$ (as appropriate) in which R^{7a} and/or R^{7b} (as appropriate) represent H, using a compound of formula XVIIIA,

 $R^{7c}L^1$ XVIIIA

wherein R^{7c} represents C_{1-6} alkyl and L^1 is as defined above;


- 5 (t) conversion of one R⁶ substituent to another; or
 - (u) deprotection of a protected derivative of a compound of formula I as defined in Claim 1.
- 21. A compound of formula II as defined in Claim 20, or a protected derivative thereof.
 - 22. A compound of formula IV as defined in Claim 20, or a protected derivative thereof.
 - 23. A compound of formula VIII as defined in Claim 20, or a protected derivative thereof



10


wherein R⁴, R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R⁶, A, B and D are as defined in Claim 1, or a protected derivative thereof.

25. A compound of formula XXII,




wherein R^1 , R^{5a} , R^{5b} , R^{5d} , R^{5e} , R^{5f} and X are as defined in Claim 1, or a protected derivative thereof

26. A process for the preparation of a compound of formula VIII, XX, XXII or XXXV (as defined herein, in which, in all cases, R^{5c} and R^{5d} both represent H), which comprises reaction of a compound of formula XXXVI,



- wherein R^z represents H or -C(O)XR¹ and R¹, R^{5a}, R^{5b}, R^{5e}, R^{5f} and X are as defined in Claim 1, or a protected derivative thereof, with (as appropriate) either:
 - (1) a compound of formula XXXVII,



or a protected derivative thereof, wherein R4, R6, A, B and D are as defined

- 5 in Claim 1; or
 - (2) NH₃ (or a protected derivative thereof), in all cases in the presence of a formaldehyde.

and 7